Decreased p66Shc promoter methylation in patients with end-stage renal disease

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 12, 2007, Pages 1764-1770

  Geisel, Jürgen ^a   Schorr, Heike ^a   Heine, Gunar H ^a   Bodis, Marion ^a   Hübner, Ulrich ^a   Knapp, Jean Pierre ^a   Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; DNA methylation; Homocysteine; p66Shc; Pyrosequencing

Indexed keywords

8 ISOPROSTANE; HOMOCYSTEINE; METHYLTRANSFERASE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

AGED; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENOME; HUMAN; HUMAN CELL; KIDNEY FAILURE; MALE; METHYLATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BASE SEQUENCE; DNA METHYLATION; DNA PRIMERS; GENE EXPRESSION REGULATION; HUMANS; KIDNEY FAILURE, CHRONIC; PROMOTER REGIONS (GENETICS);

MUS;

EID: 36849031811     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.357     Document Type: Conference Paper

References (27)

1. Bird A. The essentials of DNA methylation. Cell 1992;70:5-8.
2. Tazi J, Bird A. Alternative chromatin structure at CpG islands. Cell 1990;60:909-20.
3. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001;293:1068-70.
4. Dong C, Yoon W, Goldschmidt-Clermont PJ. DNA methylation and atherosclerosis. J Nutr 2002;132:2406S-9S.
5. Huang Y, Peng K, Su J, Huang Y, Yizhou X, Wang S. Different effects of homocysteine and oxidized low density lipoprotein on methylation status in the promoter of the estrogen receptor a gene. Acta Biochim Biophys Sin 2007;39:19-26.
6. Poirier LA. The effect of diet, genetics and chemicals on toxicity and aberrant DNA methylation: an introduction. J Nutr 2002;132:2336S-9S.
7. Castro R, Rivera I, Blom HJ, Jacobs C, Tavares de Almeida I. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherit Metab Dis 2006;29:3-20.
8. Baigent C, Burbury K. Premature cardiovascular disease in chronic renal failure. Lancet 2000;256:147-52.
9. Ritz E. Atherosclerosis in dialyzed patients. Blood Purif 2004;22:28-37.
10. Zanetti M, Barazzoni R, Bosutti A, Stocca A, Grassi G, Guarnieri G. Vascular sources of oxidative stress: implications for uremia-related cardiovascular disease. J Renal Nutr 2007;17:53-6.
11. Herrmann W, Obeid R. Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients. Clin Chem Lab Med 2005;43:1039-47.
12. Castro R, Rivera I, Struys EA, Jansen EE, Ravasco P, Camilo ME, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 2003;49:1292-6.
13. Migliaccio E, Giorgio M, Pelicci PG. Apoptosis and aging: role of p66Shc redox protein. Antioxid Redox Signal 2006;8:600-8.
14. Napoli C, Martin-Padura I, de Nigris F, Giorgio M, Mansueto G, Somma P, et al. Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. Proc Natl Acad Sci USA 2003;100:2112-6.
15. Camici GG, Schiavoni M, Francia P, Bachschmid M, Martin-Padura I, Hersberger M, et al. Genetic deletion of p66Shc adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci USA 2007;104:5217-22.
16. Ventura A, Luzi L, Pacini S, Baldari CT, Pelicci PG. The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter. J Biol Chem 2002;277:22370-6.
17. Gellinek H, van Oppenraaij-Emmerzaal D, van Rooij A, Struys EA, den Heijer M, Blom HJ. Stable-isotope liquid chromatography-electrospray injection tandem mass spectrometry method for fast, selective measurement of S-adenosylmethionine and S-adenosylhomocysteine in plasma. Clin Chem 2005;51:1478-92.
18. Issa JP, Gharibyran V, Cortes J, Jelinek J, Morris G, Verstovsek S, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukaemia resistant to imatinib mesylate. J Clin Oncol 2005;23:3948-56.
19. Geisel J, Schorr H, Bodis M, Isber S, Hübner U, Knapp JP, et al. The vegetarian lifestyle and DNA methylation. Clin Chem Lab Med 2005;43:1164-9.
20. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, et al. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 2005;29:221-33.
21. Gresham J, Margiotta P, Palad AJ, Somers KD, Blackmore PF, Wright GL, et al. Involvement of Shc in the signaling response of human prostate tumor cell lines to epidermal growth factor. Int J Cancer 1998;11:923-7.
22. Zaina S, Lindholm MW, Lund G. Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia. J Nutr 2005;135:5-8.
23. Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003;361:1693-9.
24. Stenvinkel P, Karimi M, Johansson S, Axelsson J, Suliman M, Lindholm B, et al. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease? J Int Med 2007;261:488-99.
25. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, et al. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 2002;58:190-7.
26. Pagnin E, Fadini G, de Toni R, Tiengo A, Calò L, Avogaro A. Diabetes induces p66Shc gene expression in human peripheral blood mononuclear cells: relationship to oxidative stress. J Clin Endocrinol Metab 2005;90:1130-6.
27. Pezzicoli A, Ulivieri C, Capitani N, Ventura A, Pelicci P, Baldari CT. Expression in T-cells of the proapoptotic protein p66Shc is controlled by promoter demethylation. Biochem Biophys Res Commun 2006;349:322-8.